New obesity drug tested in kidney patients: dosing clues sought
NCT ID NCT07141030
First seen Nov 21, 2025 · Last updated Jun 19, 2026 · Updated 21 times
Summary
This early-stage study tests a single dose of the drug GZR18 in 32 adults who are overweight or obese, some with mild to severe kidney problems and some with normal kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to find the right dose for people with kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gan & Lee Pharmaceuticals
RECRUITINGBeijing, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GZR18 injection
What this could lead to
If successful, this study could help doctors determine the right dose of GZR18 for people with kidney problems, making treatment safer and more effective.
What could go wrong
This is a very early phase 1 study with only 32 participants, so results may not apply to everyone. The drug may still have side effects or fail in later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.